Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 1;210(3):344-53.
doi: 10.1093/infdis/jiu141. Epub 2014 Mar 8.

Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children

Melissa D Conrad  1 , Norbert LeClair  1 , Emmanuel Arinaitwe  2 , Humphrey Wanzira  2 , Abel Kakuru  2 , Victor Bigira  2 , Mary Muhindo  2 , Moses R Kamya  3 , Jordan W Tappero  4 , Bryan Greenhouse  1 , Grant Dorsey  1 , Philip J Rosenthal  1
Affiliations

Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children

Melissa D Conrad et al. J Infect Dis. .

Abstract

Background: Artemisinin-based combination therapies, including artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP), are recommended to treat uncomplicated falciparum malaria. Sensitivities to components of AL and DP are impacted by polymorphisms in pfmdr1 and pfcrt. We monitored changes in prevalences of polymorphisms in Tororo, Uganda, from 2008 to 2012.

Methods: Polymorphic loci in pfmdr1 and pfcrt were characterized in samples from 312 children randomized to AL or DP for each episode of uncomplicated malaria (50 samples per arm for each 3-month interval) utilizing a fluorescent microsphere assay. Treatment outcomes and impacts of prior therapies were also characterized.

Results: Prevalence increased significantly over time for pfmdr1 N86 (AL: odds ratio [OR], 2.08 [95% confidence interval {CI}, 1.83-2.38]; DP: 1.41 [95% CI, 1.25-1.57]), pfmdr1 D1246 (AL: 1.46 [95% CI, 1.29-1.64]; DP: 1.36 [95% CI, 1.23-1.50]), and pfcrt K76 (AL: 3.37 [95% CI, 1.85-6.16]; DP: 5.84 [95% CI, 1.94-17.53], and decreased for pfmdr1 Y184 (AL: 0.78 [95% CI, .70-.86]; DP: 0.84 [95% CI, .76-1.50]); changes were consistently greater in the AL arm. Recent AL treatment selected for pfmdr1 N86, D1246, and 184F in subsequent episodes; DP selected for the opposite alleles.

Conclusions: Genotypes with decreased sensitivity to AL components increased over time. This increase was greater in children receiving AL, suggesting that the choice of treatment regimen can profoundly influence parasite genetics and drug sensitivity.

Clinical trials registration: NCT00527800.

Keywords: Plasmodium falciparum; artemether-lumefantrine; dihydroartemisinin-piperaquine; pfcrt; pfmdr1.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trial and experimental profile. Abbreviations: AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine.
Figure 2.
Figure 2.
Allele prevalences over time. Prevalences, each based on analysis of 50 samples per treatment arm, are shown over 3-month intervals for wild-type, mixed, and mutant alleles of pfmdr1 86, 184, and 1246; pfcrt 76; and pfmrp1 876 and 1466. Frequency curves, based on MalHaploFreq frequency estimations for each year, are superimposed; error bars represent the 95% confidence intervals for the estimates. Abbreviations: AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine.
Figure 3.
Figure 3.
Impact of prior therapy on allele prevalences. The prevalences of wild-type, mixed, and mutant sequences at the indicated alleles are shown for samples from episodes that emerged within the indicated time after a prior treatment with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP). Based on consideration of the distribution of recurrent malaria episodes over time, samples from episodes that emerged more than 56 days and 70 days after treatment are considered not to be under selection for AL and DP, respectively. Asterisks indicate wild-type allele prevalences that are significantly different from those for samples not under selection (P < .05, χ2 test). Abbreviations: AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Guidelines for the treatment of malaria. Geneva, Switzerland: WHO; 2010.
    1. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181–92. - PubMed
    1. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009 CD007483. - PMC - PubMed
    1. Dorsey G, Kamya MR, Singh A, Rosenthal PJ. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis. 2001;183:1417–20. - PubMed
    1. Four Artemisinin-Based Combinations Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119. - PMC - PubMed

Publication types

Associated data